[Use of cryoprecipitate in combined therapy of acute purulent pyelonephritis].
The treatment of 120 patients with acute purulent pyelonephritis (APP) brought about the following results. 86% patients given standard therapy showed deterioration of their condition, DIC syndrome and inflammatory process were not cured, pyoinflammatory process in the kidney continued. On the contrary, 84.1% patients on combined conservative treatment improved: DIC syndrome and active inflammation relieved, fibronectin content, IgA, IgM and IgG levels rose. Ultrasonic examination and dopplerography indicated that combined conservative therapy including cryoprecipitate arrested development of a purulent focus in the kidney, reestablished intraorganic circulation. Mean stay in hospital was 13.9 days.
Neĭmark
A I
AI
Gatkin
M Ia
MIa
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy* / Q000209:etiology; D004359:Drug Therapy, Combination; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use*; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013492:Suppuration / Q000188:drug therapy; D013577:Syndrome; D016896:Treatment Outcome; D014463:Ultrasonography
D007136:Immunoglobulins; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen